Journal Logo

Articles by B. Fan

IVOSIDENIB (AG-120) INDUCES DURABLE REMISSIONS AND TRANSFUSION INDEPENDENCE IN PATIENTS WITH IDH1-MUTANT NEWLY-DIAGNOSED AML: UPDATED RESULTS FROM A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY: PS1025

Roboz, G. J.; DiNardo, C. D.; Stein, E. M.; More

HemaSphere. 3:461-462, June 2019.

IVOSIDENIB (AG-120) INDUCES DURABLE REMISSIONS AND TRANSFUSION INDEPENDENCE IN PATIENTS WITH IDH1-MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME IN A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY: PS1337

Foran, J. M.; DiNardo, C. D.; Watts, J. M.; More

HemaSphere. 3:610-611, June 2019.